SCI Abstract

search
+
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635–48.A...
Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia
Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia
The transcription factor MYB is frequently upregulated in T-cell acute lymphoblastic leukemia (T-ALL), a hematological mal...
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
The use of measurable residual disease (MRD) as a biomarker for prognostication, risk stratification, and therapeutic deci...
YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis
YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis
B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive malignancy characterized by the aberrant accumulation of imma...
Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts
Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts
It is estimated that 10% of individuals with a myeloid malignancy carry a germline susceptibility. Using the genome-first ...
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms
Histiocytic neoplasms are a rare group of diseases with significant morbidity due to histiocytic infi...
Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS
Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS
Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset au...
Genomic profiling of circulating tumor DNA for childhood cancers
Genomic profiling of circulating tumor DNA for childhood cancers
The utility of circulating tumor DNA (ctDNA) analysis has not been well-established for disease detection and monitoring o...
Space exploration and cancer: the risks of deeper space adventures
Afshinnekoo E, Scott RT, MacKay MJ, Pariset E, Cekanaviciute E, Barker R, et al. Fundamental biological features of spacef...
Hemolytic versus malproductive anemia in large granular lymphocytic leukemia
Hemolytic versus malproductive anemia in large granular lymphocytic leukemia
Large granular lymphocytic leukemia (LGLL) can be defined as a chronic clonal proliferation of either cytotoxic T- (CTLs) ...
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group
Myelofibrosis (MF) is a Philadelphia chromosome (BCR::ABL1)-negative myeloproliferative neoplasm, a hallmark of which is p...
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leuk...
The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells
The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells
Selinexor, a first-in-class exportin1 (XPO1) inhibitor, is an attractive anti-tumor agent because of its unique mechanisms...
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma
The interaction between stromal and tumor cells in tumor microenvironment is a crucial factor in Mantle cell lymphoma (MCL...
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition
SF3B1 mutations frequently occur in cancer yet lack targeted therapies. Clinical trials of XPO1 inhibitors, selinexor and ...
PHF6 suppresses self-renewal of leukemic stem cells in AML
PHF6 suppresses self-renewal of leukemic stem cells in AML
Acute myeloid leukemia is characterized by uncontrolled proliferation of self-renewing myeloid progenitors accompanied by ...
STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
Hematopoietic stem and progenitor cells (HSPCs) maintain blood-forming and immune activity, yet intrinsic regulators of HS...
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Tyrosine kinase inhibitor (TKI) therapy discontinuation with the aim of achieving treatment-free remission (TFR) is becomi...
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
Systemic Mastocytosis (SM) is a multifaceted clinically heterogeneous disease. Advanced SM (AdvSM) comprises three entitie...
Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression in myelodysplastic neoplasms
Oelschlaegel U, Winter S, Sockel K, Epp K, Schadt J, Röhnert MA, et al. MDS-PB13 score—blood based detection of aberrancie...
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22+ mal...
Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease
Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease
Thrombopoietin (Tpo), which binds to its specific receptor, the Mpl protein, is the major cytokine regulator of megakaryop...
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
Loss-of-function mutations in NFKBIE, which encodes for the NF-κB inhibitor IκBε, are frequent in chronic l...
Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors
Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors
Extramedullary multiple myeloma (EMM) is an aggressive form of multiple myeloma (MM). This study represents the most compr...
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia
Acute myeloid leukemia (AML) is a malignancy with a poor prognosis. The expansion of leukemic cells is associated with the...
Luigi (Gino) Chieco-Bianchi: a man linking hematological and virological research
Luigi (Gino) Chieco-Bianchi: a man linking hematological and virological research
Credit: Courtesy of G. PizzoloLuigi Chieco Bianchi, called Gino by his friends, died in Padua on June 23rd 20...
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is still an incurable disease, with many patients developing resistance to conventional...
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of ...
Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232
Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232
Osteonecrosis is a significant toxicity of acute lymphoblastic leukemia (ALL) therapy. In retrospective analyses, superior...
Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States
Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States
Gundesen MT, Lund T, Moeller HEH, Abildgaard N. Plasma cell leukemia: definition, presentation, and treatment. Curr Oncol ...
Load More
format_indent_increase